ADAM10 (A Disintegrin and Metalloproteinase), known as α-secretase that plays a critical role in APP cleavage, is downregulated in AD but is increased (hsa-miR-34a-5p) in nilotinib-treated patients. Here, APP is linked to Alzheimer disease.